Group 1: New Stock Offerings - Jichuan Pharmaceutical (600566) has a tender offer period from June 18, 2025, to July 17, 2025[1] - *ST Yazhen (603389) has a tender offer period from June 10, 2025, to July 9, 2025[1] Group 2: Delisting Information - *ST Gongzhi (000584) will enter the delisting arrangement period starting June 20, 2025[1] - Delisting Haiyue (600387) has 14 trading days remaining until the last trading day[1] - Renle Tui (002336) has 13 trading days remaining until the last trading day[1] - Delisting Longyu (603003) has 10 trading days remaining until the last trading day[1] - Delisting Pengbo (600804) has 10 trading days remaining until the last trading day[1] - Longjin Tui (002750) has 8 trading days remaining until the last trading day[1] Group 3: Abnormal Fluctuations - Lianhua Technology (002250) reported severe abnormal fluctuations[1] - ST Kailin (002425) reported abnormal fluctuations[1] - ST Xianfeng (002141) reported abnormal fluctuations[1] - ST Shihuan (000518) reported abnormal fluctuations[1]

转自：咸宁新闻网 智能化建设作为企业高质量发展的核心引擎，亦是中医药行业现代化与标准化发展的根基。多年来，济川药业 坚持创新驱动变革发展，秉承品质至上的质量理念，在中成药的全流程生产中，深度融入智能技术，实现了从 仓储管理到生产环节的全面智能化升级，为中药产业的现代化发展注入了强劲动力。日前，济川药业集团有限 公司凭借"基于全生命周期可靠追溯的中药口服液智能工厂"项目成功入选2025年江苏省先进级智能工厂 在仓储管理智能化方面：济川药业通过引入堆垛机、机器人码盘机、箱输送机等自控设备，结合先进的 WMS(仓储管理系统)和WCS(仓储控制系统)，实现了药品存储、分拣及出入库全流程自动化作业。显著提升空 间利用率的同时，确保了库存数据的精准度，为生产计划的精准执行提供了有力保障。 在生产环节人机协同方面：在生产线上，济川药业整合了贴签、压塑、装盒、喷码、检重、装箱等全流程工 序，实现了人机协同作业与柔性生产。电眼实时监测产品触发贴标，视觉检测设备全程保障装盒质量，机械手 臂与智能设备紧密配合，确保了每一道工序的高效与精准。 在在线智能检测技术方面：济川药业引入了基于智能灯检机的在线智能检测技术，通过先进视觉成像技 ...

Group 1 - The core point of the news is the internal equity structure adjustment within the family of the actual controller of Jichuan Pharmaceutical, leading to a mandatory general offer for shares, initiated by Cao Fei, which does not aim to terminate the company's listing status [1] - The equity transfer involves Cao Longxiang transferring 10.10% of his shares in Jichuan Holdings to his son, Cao Fei, resulting in Cao Fei holding 60% of Jichuan Holdings and indirectly controlling 5.17 billion shares of the listed company, accounting for 56.07% of the total share capital [1] - The mandatory general offer will cover all freely tradable shares held by other shareholders, totaling 351 million shares, which is 38.06% of the company's total share capital, with an offer price of 26.93 yuan per share, valid for 30 days from June 18, 2025, to July 17, 2025 [1][2] Group 2 - The total maximum funding required for the general offer is approximately 94.48 billion yuan, sourced from the acquirer's own funds and legally raised funds, with 18.95 billion yuan deposited as a performance guarantee [2] - The transition of control from one generation to the next is a significant trend in the industry, with over 80% of private enterprises in China being family-owned, and many are currently undergoing generational handovers [2] - The company aims to maintain stable development of its core business while promoting innovation and transformation, focusing on a dual pillar layout of traditional Chinese medicine and chemical medicine, and accelerating the launch of new products through strategic cooperation and technology introduction [3]

Core Viewpoint - The company has received a takeover offer from Mr. Cao Fei, which triggers a mandatory general offer due to the increase in shareholding above 30% [2][4]. Summary by Sections Offer Details - The offer price is set at 26.93 yuan per share, with a total of 350,841,357 shares being offered, representing 38.06% of the company's issued shares [4][5]. - The offer period lasts for 30 days, from June 18, 2025, to July 17, 2025, during which shareholders cannot withdraw their acceptance in the last three trading days [7]. Shareholding Changes - Mr. Cao Longxiang plans to transfer 10.10% of his shares in Jiangsu Jichuan Holding Group to his son, Mr. Cao Fei, making Mr. Cao Fei the controlling shareholder of Jichuan Holding with 60% ownership [2][4]. - Following the transfer, both Mr. Cao Fei and Mr. Cao Longxiang will be the joint actual controllers of the listed company, ensuring that the company's independence remains unaffected [2][4]. Financial Arrangements - The total maximum funding required for the offer is 18.95 billion yuan, with at least 20% of this amount deposited as a performance guarantee [6]. - The funding for the offer comes from the acquirer's own funds and legally raised funds, with no involvement from the listed company or its affiliates [6][7]. Compliance and Procedures - The acquirer, Mr. Cao Fei, does not require any authorization or approval from relevant institutions to make the offer [4]. - The offer is made in compliance with the Securities Law and the Takeover Management Measures, ensuring that the offer price is based on the weighted average price of the company's shares over the previous 30 trading days [5].

证券代码： 600566 证券简称： 济川药业 公告编号： 2025-042 湖北济川药业股份有限公司 关于收到要约收购报告书的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 1 2025 年 6 月 11 日，公司实际控制人曹龙祥先生与其子曹飞先生签署《江 苏济川控股集团有限公司股权转让协议》，曹龙祥先生拟将其所持江苏 济川控股集团有限公司（以下简称"济川控股"）10.10%的股权转让给 曹飞先生。本次股权转让完成后，曹飞先生持有济川控股 60%的股权， 成为济川控股的控股股东，并通过济川控股、西藏济川企业管理有限公 司（以下简称"西藏济川"）间接控制上市公司 516,757,360 股股份， 占上市公司总股本的 56.07%，超过上市公司已发行股份的 30%，从而 触发全面要约收购义务。 本次股权转让系公司实际控制人曹龙祥先生向其子曹飞先生转让部分 济川控股股权，属于实际控制人家族内部的股权结构调整行为，不会影 响公司的独立性，不会对公司经营产生重大影响。本次转让完成后，上 市公司控股股东不变， ...

证券代码： 600566 证券简称： 济川药业 公告编号： 2025-043 湖北济川药业股份有限公司 关于曹飞先生要约收购公司股份的申报公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 湖北济川药业股份有限公司（以下简称"济川药业"或"公司"）于 2025 年 6 月 12 日收到曹飞先生(以下简称"收购人")发来的《湖北济川药业股份有 限公司要约收购报告书》(以下简称"《要约收购报告书》")等文件，就收购人 要约收购的有关事项作出申报公告如下: 一、 本次要约收购申报的有关事项 （一）要约收购的提示 《要约收购报告书》披露后 30 日内，本公司将在上海证券交易所网站 （http://www.sse.com.cn）发布 3 次要约收购提示性公告。 （二）要约收购情况 1 预受要约申报代码：706034 申报简称：济川收购 要约收购支付方式：现金 要约收购价格：26.93 元/股 要约收购数量：全面要约，拟收购股份数量为 350,841,357 股，占济川 药业总股份的比例为 38.06%。 要约收购有效期 ...

证券简称：济川药业 证券代码：600566.SH 湖北济川药业股份有限公司 要约收购报告书 | 上市公司名称： | 湖北济川药业股份有限公司 | | --- | --- | | 股票上市地点： | 上海证券交易所 | | 股票简称： | 济川药业 | | 股票代码： | 600566.SH | | 收购人： 曹飞 | | | --- | --- | | 住所 ： | 上海市黄浦区**** | | 一致行动人： 曹龙祥 | | | 住所 ： | 江苏省泰兴市**** | | 一致行动人： | 江苏济川控股集团有限公司 | | 住所 ： | 泰兴市黄桥工业园区兴业标房 号厂房内 1 | | 一致行动人： | 西藏济川企业管理有限公司 | | 住所 ： | 拉萨经济技术开发区大连路以西、格桑路以北总部 | | | 经济基地 B（栋）3 单元 4 层 404 号 | 收购方财务顾问： 签署日期：二零二五年六月 湖北济川药业股份有限公司 要约收购报告书 特别提示 本部分所述的词语或简称与本报告书"释义"部分所定义的词语或简称具 有相同的含义。 1、本次股权转让前，济川控股持有上市公司 416,757,360 股股份（占 ...

北京植德律师事务所 关于 《湖北济川药业股份有限公司要约收购报告书》的 法律意见书 植德(证)字[2025]0024-1 号 | 释 人 | | --- | | 一、收购人及其一致行动人的基本情况 | | 二、要约收购的目的 . | | 三、要约收购方案 . | | 四、收购资金来源 . | | 五、后续计划 . | | 六、对上市公司的影响分析 . | | 七、与上市公司之间的重大交易 . | | 八、前六个月内买卖上市公司股份的情况 . | | 九、《要约收购报告书》的格式与内容 | | 十、参与本次要约收购的专业机构 | | 十一、结论意见 | l 释 义 本法律意见书中,除非文义另有所指,下列词语或简称具有如下含义: | 济川药业、公司、上市公司 | 분 | 湖北济川药业股份有限公司 | | --- | --- | --- | | 收购人 | 블 | ■ K | | 济川控股 | 指 | 江苏济川控股集团有限公司 | | 西藏济川 | 指 | 西藏济川企业管理有限公司 | | 一致行动人 | 指 | 曹龙祥、济川控股、西藏济川 | | 本次股权转让/本次转让 | 指 | 曹龙祥将其持有的济川控股10. ...

曹飞 要约收购 北京博星证券投资顾问有限公司 关于 湖北济川药业股份有限公司 之 财务顾问报告 二〇二五年六月 北京博星证券投资顾问有限公司 财务顾问报告 重要提示 本部分所述的词语或简称与本报告书"释义"部分所定义的词语或简称具有相 同的含义。 1、本次股权转让前，济川控股持有上市公司 416,757,360 股股份（占上市公司 总股本的 45.22%），为上市公司控股股东，曹龙祥持有济川控股 50.10%股权为其 控股股东，曹飞持有济川控股 49.90%股权；西藏济川为济川控股全资子公司，持有 上市公司 100,000,000 股股份（占上市公司总股本的 10.85%）；曹龙祥持有上市公 司 46,838,458 股股份（占上市公司总股本的 5.08%）。本次股权转让前，上市公司 实际控制人为曹龙祥，曹龙祥与收购人曹飞系父子关系。 2025 年 6 月 11 日，曹龙祥与曹飞签署《股权转让协议》，曹龙祥将其持有的 济川控股 10.10%股权以 1,010 万元价格转让给曹飞，股权转让完成后，曹飞持有济 川控股 60%股权，为济川控股控股股东，并通过济川控股、西藏济川间接控制上市 公司 516,757,36 ...

Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Positive" (maintained) [1] Core Insights - The flu virus is a highly pathogenic pathogen, and the development of new mechanism drugs is imperative [4] - The flu is a common respiratory infectious disease with a high transmission rate, affecting approximately 1 billion people globally each year, with 300,000 to 500,000 severe cases and 290,000 to 650,000 deaths due to flu-related respiratory diseases [4][15] - The domestic flu drug market has exceeded 10 billion yuan, with Oseltamivir holding over 80% market share, while Baloxavir has seen rapid growth from 0.07 billion yuan in 2022 to 0.63 billion yuan in 2023 [6][36] Summary by Sections 1. Flu Virus and Drug Development - The flu virus is categorized into four types: A, B, C, and D, with A and B being the primary types responsible for widespread outbreaks [17][20] - The main drug targets during flu infection include the surface proteins Hemagglutinin (HA) and Neuraminidase (NA), with RNA polymerase inhibitors emerging as the mainstream research target in antiviral drug development [5][26] 2. Market Dynamics - The flu drug market in China is projected to grow significantly, with new domestic drugs expected to launch in 2025, enhancing sales potential and company performance [7][36] - The sales of flu drugs in the domestic market reached 11.405 billion yuan in 2023, with Oseltamivir accounting for 86.48% of the market share [36] 3. Investment Recommendations - Recommended stocks include Jichuan Pharmaceutical and Health元, with beneficiaries including Zhongsheng Pharmaceutical and Xiansheng Pharmaceutical [7]